Queen's School of Business Presentation
Issue link: http://invivo.uberflip.com/i/1501332
Dialogues in Cytomegalovirus 7 CMV Management in the Post-DNA Polymerase Inhibitor Era Financial Disclosures Dr. Matthew Cheng has received an honorarium from Takeda Canada for this article. Correspondence Dr. Matthew Cheng Email: matthew.cheng@mcgill.ca References 1. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States: the national health and nutrition examination surveys, 1988-2004. Clin Infect Dis. 2010;50(11):1439-47. 2. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J Gen Virol. 2006;87(Pt 7):1763-79. 3. Meesing A, Razonable RR. New developments in the management of cytomegalovirus infection a›er transplantation. Drugs. 2018;78(11):1085-103. 4. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, et al. Evidence for a bidirectional relationship between cytomegalovirus replication and acute gra›-versus-host disease. Biol Blood Marrow Transplant. 2010;16(9):1309-14. 5. Lumbreras C, Manuel O, Len O, ten Berge IJ, Sgarabotto D, Hirsch HH. Cytomegalovirus infection in solid organ transplant recipients. Clin Microbiol Infect. 2014;20 Suppl 7:19-26. 6. Jorgenson MR, Descourouez JL, Cardinale B, Lyu B, Astor BC, Garg N, et al. Risk of opportunistic infection in kidney transplant recipients with cytomegalovirus infection and associated outcomes. Transpl Infect Dis. 2019;21(3):e13080. 7. Yong MK, Ananda-Rajah M, Cameron PU, Morrissey CO, Spencer A, Ritchie D, et al. Cytomegalovirus reactivation is associated with increased risk of late-onset invasive fungal disease a›er allogeneic hematopoietic stem cell transplantation: a multicenter study in the current era of viral load monitoring. Biol Blood Marrow Transplant. 2017;23(11):1961-7. 8. Hill JA, Mayer BT, Xie H, Leisenring WM, Huang ML, Stevens- Ayers T, et al. The cumulative burden of double-stranded DNA virus detection a›er allogeneic HCT is associated with increased mortality. Blood. 2017;129(16):2316-25. 9. Haidar G, Singh N. Viral infections in solid organ transplant recipients: novel updates and a review of the classics. Curr Opin Infect Dis. 2017;30(6):579-88. 10. Crumpacker CS. Ganciclovir. N Engl J Med. 1996;335(10):721-9. 11. Lea AP, Bryson HM. Cidofovir. Drugs. 1996;52(2):225-30; discussion 31. 12. Crumpacker CS. Mechanism of action of foscarnet against viral polymerases. Am J Med. 1992;92(2A):3S-7S. 13. Bacigalupo A, Boyd A, Slipper J, Curtis J, Clissold S. Foscarnet in the management of cytomegalovirus infections in hematopoietic stem cell transplant patients. Expert Rev Anti Infect Ther. 2012;10(11):1249-64. 14. Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L, et al. The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid- organ Transplantation. Transplantation. 2018;102(6):900-31. 15. Chemaly RF, Chou S, Einsele H, Griffiths P, Avery R, Razonable RR, et al. Definitions of resistant and refractory cytomegalovirus infection and disease in transplant recipients for use in clinical trials. Clin Infect Dis. 2019;68(8):1420-6. 16. Prevymis Product Monograph, Merck Canada. 2017. Available from: https://pdf.hres.ca/dpd_pm/00041967.PDF. 17. Goldner T, Hewlett G, Ettischer N, Ruebsamen-Schaeff H, Zimmermann H, Lischka P. The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase. J Virol. 2011;85(20):10884-93. 18. Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, et al. Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med. 2017;377(25):2433-44. 19. Marty FM, Ljungman PT, Chemaly RF, Wan H, Teal VL, Butterton JR, et al. Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantation. Am J Transplant. 2020;20(6):1703-11. 20. Gonzalez-Bocco IH et al. Letermovir treatment for refractory or resistant cytomegalovirus infection or disease with concurrent organ dysfunction: an interim analysis of a Phase 2 open label study. Open Forum Infect Dis 2022 Dec; 9(Suppl 2): ofac492.024. 21. Limaye AP et al. LB2307. Safety and efficacy of letermovir (LET) versus valganciclovir (VGCV) for prevention of cytomegalovirus (CMV) disease in kidney transplant recipients (KTRs): a phase 3 randomized study. Open Forum Infectious Diseases. 2022 Dec;9(Suppl 2):ofac492.1897. doi:10.1093/ofid/ofac492.1897 22. Chou S. Rapid in vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance. Antimicrob Agents Chemother. 2015;59(10):6588-93. 23. Livtencity Product Monograph. Takeda Canada. Sept. 15, 2022. 24. Krosky PM, Baek MC, Coen DM. The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress. J Virol. 2003;77(2):905-14. 25. Winston DJ, Young JA, Pullarkat V, Papanicolaou GA, Vij R, Vance E, et al. Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo- controlled, dose-ranging study. Blood. 2008;111(11):5403-10. 26. Marty FM, Ljungman P, Papanicolaou GA, Winston DJ, Chemaly RF, Strasfeld L, et al. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial. Lancet Infect Dis. 2011;11(4):284-92. 27. Marty FM, Boeckh M. Maribavir and human cytomegalovirus- what happened in the clinical trials and why might the drug have failed? Curr Opin Virol. 2011;1(6):555-62. 28. Avery RK, Marty FM, Strasfeld L, Lee I, Arrieta A, Chou S, et al. Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. Transpl Infect Dis. 2010;12(6):489-96. 29. Papanicolaou GA, Silveira FP, Langston AA, Pereira MR, Avery RK, Uknis M, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double- blind, phase 2 study. Clin Infect Dis. 2019;68(8):1255-64.